Clinic
Regents of the University of Michigan
Regents of the University of Michigan was paid $317.77M by Medicaid between Jan 2018 and Dec 2024, across 1275 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 18% of everything it billed.
33Billing provider infoREGENTS OF THE UNIVERSITY OF MICHIGAN
ANN ARBOR, MI 48109
ANN ARBOR, MI 48109
33aNPI1003878539assigned 04/03/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$317.77M
24GClaims8,665,549
24DCodes billed1275
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in Michigan
Rank by total paid#1 of 114
Median peer was paid$316K
This provider vs. median1,007×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, DAVID controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,133,525 | $41.08M | |
| 2019 | 1,185,575 | $43.06M | |
| 2020 | 1,016,427 | $35.14M | |
| 2021 | 1,277,728 | $48.43M | |
| 2022 | 1,398,042 | $53.09M | |
| 2023 | 1,471,871 | $53.93M | |
| 2024incomplete | 1,182,381 | $43.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18% | 1,244,348 | 998,265 | $56.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 53,698 | 48,644 | $28.78M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.5% | 53,170 | 50,127 | $11.27M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.4% | 1,703 | 1,309 | $7.64M |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2.2% | 5,042 | 2,756 | $7.00M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.9% | 2,371 | 2,360 | $6.13M |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 1.9% | 6,340 | 5,724 | $5.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.7% | 44,028 | 41,162 | $5.45M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.7% | 13,659 | 13,385 | $5.36M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 34,454 | 23,050 | $5.19M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.5% | 3,427 | 3,072 | $4.82M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 1.2% | 1,629 | 1,379 | $3.96M |
1263 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 16,946 | $3.67M |
| 77386 | 1.1% | 12,763 | $3.36M | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 38,068 | $2.86M |
| J2350 | Injection, ocrelizumab, 1 mg | <1% | 216 | $2.82M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 9,337 | $2.66M |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 1,597 | $2.61M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 76,119 | $2.54M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 5,418 | $2.54M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 104,097 | $2.53M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 5,290 | $2.48M |
| J9312 | Injection, rituximab, 10 mg | <1% | 983 | $2.48M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 33,895 | $2.44M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 7,919 | $2.41M |
| 90837 | Psychotherapy session, about an hour | <1% | 29,387 | $2.08M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 52,965 | $1.98M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 34,177 | $1.93M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 31,828 | $1.81M |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 2,409 | $1.78M |
| C9399 | Unclassified drugs or biologicals | <1% | 6,769 | $1.77M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 33,210 | $1.68M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 6,775 | $1.62M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 72,622 | $1.58M |
| 72156 | <1% | 3,388 | $1.55M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 16,144 | $1.51M |
| Q3014 | Telehealth originating site facility fee | <1% | 96,147 | $1.50M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 41,318 | $1.45M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 34,985 | $1.41M |
| J2357 | Injection, omalizumab, 5 mg | <1% | 2,445 | $1.37M |
| J0178 | Injection, aflibercept, 1 mg | <1% | 1,832 | $1.36M |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 2,781 | $1.34M |
| J0490 | Injection, belimumab, 10 mg | <1% | 867 | $1.32M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 9,891 | $1.32M |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 21,867 | $1.30M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 1,554 | $1.30M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 2,352 | $1.26M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 16,391 | $1.24M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 20,642 | $1.23M |
| 95811 | <1% | 2,732 | $1.22M | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 67,664 | $1.20M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 3,305 | $1.17M |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 592 | $1.16M |
| 90677 | <1% | 6,450 | $1.08M | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 47,653 | $1.07M |
| 36430 | <1% | 5,959 | $1.06M | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 14,023 | $998K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 16,666 | $992K |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | <1% | 888 | $983K |
| 72197 | <1% | 3,656 | $979K | |
| 95782 | <1% | 1,996 | $975K | |
| 59025 | Fetal non-stress test | <1% | 10,332 | $934K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 3,824 | $922K |
| 38222 | <1% | 621 | $905K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 653 | $868K |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 872 | $845K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 14,003 | $822K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 722 | $819K |
| J9310 | Injection, rituximab, 100 mg | <1% | 351 | $816K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 13,769 | $811K |
| 74183 | <1% | 5,936 | $791K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 11,675 | $786K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 5,039 | $784K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 177 | $767K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 5,444 | $758K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 12,659 | $748K |
| G0378 | Hospital observation service, per hour | <1% | 25,007 | $715K |
| 81229 | <1% | 1,232 | $702K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,137 | $701K |
| 76770 | <1% | 13,287 | $691K | |
| 93970 | <1% | 6,701 | $684K | |
| 92587 | <1% | 5,004 | $680K | |
| 97162 | <1% | 13,636 | $660K | |
| 67311 | <1% | 773 | $658K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 1,020 | $645K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 17,599 | $626K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 50,223 | $621K |
| 80061 | Lipid panel | <1% | 60,717 | $614K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 50,220 | $613K |
| 96415 | <1% | 11,923 | $597K | |
| 31575 | <1% | 7,615 | $597K | |
| 90670 | <1% | 18,411 | $591K | |
| 95716 | <1% | 1,416 | $588K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 31,111 | $588K |
| 76857 | <1% | 11,529 | $580K | |
| 76830 | Ultrasound, transvaginal | <1% | 10,325 | $571K |
| 92523 | <1% | 5,142 | $568K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 338 | $561K |
| 52000 | <1% | 2,213 | $560K | |
| 90686 | <1% | 55,062 | $558K | |
| 49083 | <1% | 1,381 | $549K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,573 | $542K |
| 43235 | <1% | 1,618 | $540K | |
| 90651 | <1% | 8,329 | $540K | |
| 20610 | <1% | 4,273 | $532K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 7,528 | $531K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 7,130 | $518K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 7,860 | $497K |
| 64483 | <1% | 1,162 | $491K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 5,062 | $484K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 420 | $482K |
| 77334 | <1% | 1,441 | $472K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 40,648 | $452K |
| 76825 | <1% | 1,694 | $451K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 1,163 | $440K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,449 | $435K |
| 54161 | <1% | 488 | $425K | |
| 64642 | <1% | 1,397 | $422K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 10,441 | $401K |
| 70491 | <1% | 3,185 | $389K | |
| 80053 | Comprehensive metabolic panel | <1% | 223,908 | $389K |
| 90732 | <1% | 4,116 | $386K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 32,558 | $386K |
| 97161 | <1% | 7,602 | $384K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,320 | $381K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | <1% | 263 | $381K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 3,351 | $377K |
| 64615 | <1% | 3,027 | $376K | |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 318 | $359K |
| 20611 | <1% | 2,717 | $356K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,540 | $356K |
| 90750 | <1% | 2,685 | $353K | |
| 93975 | <1% | 3,424 | $350K | |
| 90378 | <1% | 361 | $350K | |
| 96367 | <1% | 11,702 | $344K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 91,313 | $344K |
| G0008 | Administration of influenza virus vaccine | <1% | 37,320 | $328K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 21,983 | $328K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,128 | $321K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 258,517 | $317K |
| 95816 | <1% | 2,227 | $315K | |
| A0210 | Non-emergency transportation: ancillary: meals-escort | <1% | 13,766 | $315K |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | <1% | 712 | $312K |
| 96409 | <1% | 2,853 | $308K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 274 | $305K |
| 76801 | <1% | 5,320 | $300K | |
| 78816 | <1% | 433 | $299K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,205 | $297K |
| 31231 | <1% | 3,693 | $297K | |
| 94060 | <1% | 2,273 | $297K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 45,767 | $296K |
| 77301 | <1% | 482 | $295K | |
| 72141 | <1% | 2,293 | $294K | |
| 77336 | <1% | 4,689 | $289K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 7,534 | $287K |
| 95951 | <1% | 929 | $286K | |
| 93451 | <1% | 196 | $284K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,804 | $283K |
| 77300 | <1% | 1,476 | $280K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 3,543 | $270K |
| 75561 | <1% | 1,073 | $267K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,461 | $266K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 31,405 | $264K |
| 95117 | <1% | 12,912 | $262K | |
| 74174 | <1% | 1,830 | $261K | |
| 58661 | <1% | 80 | $260K | |
| J9022 | Injection, atezolizumab, 10 mg | <1% | 79 | $259K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,040 | $258K |
| 76881 | <1% | 4,336 | $256K | |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | <1% | 8,634 | $253K |
| 71250 | <1% | 4,501 | $252K | |
| 94762 | <1% | 8,880 | $252K | |
| 92557 | <1% | 11,919 | $251K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 53,812 | $249K |
| 58301 | <1% | 2,085 | $249K | |
| 96127 | <1% | 16,498 | $247K | |
| 86832 | <1% | 4,216 | $242K | |
| 86833 | <1% | 4,217 | $242K | |
| 96417 | <1% | 7,136 | $242K | |
| 31622 | <1% | 506 | $241K | |
| 70496 | <1% | 1,795 | $237K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,801 | $236K |
| 97165 | <1% | 4,943 | $234K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 25,580 | $234K |
| 20680 | <1% | 235 | $233K | |
| 86900 | <1% | 40,238 | $229K | |
| 11104 | <1% | 1,480 | $228K | |
| 10005 | <1% | 752 | $227K | |
| 87507 | <1% | 2,437 | $225K | |
| 91320 | <1% | 2,101 | $223K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 2,993 | $218K |
| 97760 | <1% | 6,197 | $216K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 3,047 | $213K |
| 99385 | <1% | 3,701 | $211K | |
| 95700 | <1% | 2,281 | $209K | |
| 31579 | <1% | 1,133 | $206K | |
| 43762 | <1% | 1,554 | $204K | |
| 64405 | <1% | 1,814 | $203K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 616 | $202K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 4,727 | $201K |
| 36561 | <1% | 121 | $195K | |
| 97163 | <1% | 4,198 | $194K | |
| 72158 | <1% | 3,061 | $194K | |
| 95908 | <1% | 1,435 | $192K | |
| 74230 | <1% | 2,887 | $192K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 80,061 | $190K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 314 | $189K |
| 70543 | <1% | 1,029 | $188K | |
| 96116 | <1% | 1,581 | $187K | |
| 76536 | <1% | 5,787 | $186K | |
| 93505 | <1% | 101 | $184K | |
| 93308 | <1% | 1,921 | $181K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 3,127 | $181K |
| 97166 | <1% | 3,865 | $180K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 440 | $177K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 7,268 | $176K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 7,641 | $173K |
| 76642 | <1% | 5,112 | $171K | |
| 19083 | <1% | 228 | $169K | |
| 77066 | Tomosynthesis, mammo | <1% | 3,111 | $169K |
| 78264 | <1% | 912 | $168K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 21,301 | $167K |
| J9070 | Cyclophosphamide, 100 mg | <1% | 1,180 | $163K |
| 92235 | <1% | 1,208 | $157K | |
| 99381 | <1% | 2,739 | $157K | |
| 20553 | <1% | 1,403 | $157K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 3,450 | $157K |
| 17110 | <1% | 4,453 | $154K | |
| 95713 | <1% | 704 | $153K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 13,067 | $153K |
| 86481 | <1% | 5,024 | $153K | |
| 92579 | <1% | 7,699 | $151K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,776 | $151K |
| 77065 | Tomosynthesis, mammo | <1% | 3,520 | $151K |
| 93976 | <1% | 3,252 | $150K | |
| 93350 | <1% | 675 | $148K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 1,618 | $148K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 77,067 | $146K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 88,881 | $145K |
| 72157 | <1% | 2,668 | $143K | |
| 11102 | <1% | 1,721 | $143K | |
| 78431 | <1% | 119 | $141K | |
| 82728 | <1% | 43,050 | $140K | |
| 99383 | <1% | 2,302 | $138K | |
| 96132 | <1% | 1,807 | $137K | |
| 64493 | <1% | 305 | $135K | |
| 96910 | <1% | 4,670 | $133K | |
| 92604 | <1% | 1,858 | $133K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 510 | $129K |
| 29075 | <1% | 1,072 | $129K | |
| 93296 | <1% | 7,398 | $128K | |
| 99495 | <1% | 2,190 | $127K | |
| 92611 | <1% | 2,767 | $126K | |
| 19303 | <1% | 41 | $126K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 4,235 | $126K |
| 93923 | <1% | 2,139 | $126K | |
| 77080 | <1% | 2,378 | $125K | |
| 42830 | <1% | 105 | $123K | |
| 73221 | <1% | 1,149 | $122K | |
| 94010 | <1% | 15,645 | $121K | |
| 70486 | <1% | 2,761 | $121K | |
| 66982 | <1% | 65 | $121K | |
| 64450 | <1% | 314 | $118K | |
| 95910 | <1% | 876 | $118K | |
| 93880 | <1% | 1,231 | $117K | |
| 43264 | <1% | 223 | $117K | |
| 93226 | <1% | 2,216 | $117K | |
| 82947 | <1% | 13,741 | $115K | |
| 90480 | <1% | 3,132 | $114K | |
| 96411 | <1% | 3,086 | $114K | |
| 62370 | <1% | 836 | $114K | |
| 58100 | <1% | 1,322 | $114K | |
| 96450 | <1% | 824 | $113K | |
| 85027 | <1% | 84,409 | $113K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 1,239 | $113K |
| 92552 | <1% | 3,731 | $112K | |
| 91065 | <1% | 1,438 | $109K | |
| 81268 | <1% | 459 | $108K | |
| 86803 | <1% | 24,091 | $105K | |
| 95819 | <1% | 823 | $103K | |
| 64400 | <1% | 826 | $102K | |
| 88184 | <1% | 2,392 | $101K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 1,453 | $101K |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 124 | $100K |
| 85055 | <1% | 17,054 | $100K | |
| 88341 | <1% | 4,570 | $100K | |
| 83880 | <1% | 18,843 | $99K | |
| 78306 | <1% | 554 | $95K | |
| 74018 | <1% | 13,020 | $95K | |
| 29705 | <1% | 704 | $94K | |
| 88342 | <1% | 7,737 | $93K | |
| 93971 | <1% | 1,899 | $93K | |
| 74181 | <1% | 890 | $91K | |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 729 | $90K |
| 10060 | <1% | 1,014 | $90K | |
| 92526 | <1% | 2,067 | $88K | |
| 99386 | <1% | 1,622 | $88K | |
| 74178 | <1% | 608 | $88K | |
| 80197 | <1% | 20,279 | $87K | |
| 77338 | <1% | 531 | $86K | |
| 70487 | <1% | 973 | $84K | |
| 86235 | <1% | 9,784 | $84K | |
| 83550 | <1% | 38,486 | $82K | |
| 99382 | <1% | 1,406 | $82K | |
| 99384 | <1% | 1,369 | $81K | |
| 96112 | <1% | 955 | $81K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 9,545 | $81K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 443 | $81K |
| 51700 | <1% | 968 | $80K | |
| 86592 | <1% | 27,994 | $80K | |
| 76000 | <1% | 2,776 | $78K | |
| 57454 | <1% | 555 | $78K | |
| 58558 | <1% | 62 | $77K | |
| 31615 | <1% | 316 | $77K | |
| 11100 | <1% | 590 | $76K | |
| 67228 | <1% | 281 | $76K | |
| 92524 | <1% | 1,474 | $76K | |
| 83970 | <1% | 10,910 | $76K | |
| 20550 | <1% | 565 | $75K | |
| 97597 | <1% | 1,364 | $75K | |
| 92582 | <1% | 3,051 | $75K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,186 | $74K |
| 92626 | <1% | 1,911 | $74K | |
| 84403 | <1% | 9,243 | $73K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 45,602 | $73K |
| 76882 | <1% | 2,801 | $73K | |
| 92610 | <1% | 1,877 | $72K | |
| 95076 | <1% | 274 | $72K | |
| 82607 | <1% | 17,220 | $71K | |
| 52287 | <1% | 82 | $71K | |
| 51729 | <1% | 247 | $71K | |
| 94726 | <1% | 2,744 | $69K | |
| 95909 | <1% | 516 | $69K | |
| 29065 | <1% | 565 | $68K | |
| 77412 | <1% | 620 | $68K | |
| 11900 | <1% | 2,074 | $68K | |
| 80076 | <1% | 35,988 | $67K | |
| 70480 | <1% | 944 | $66K | |
| 97542 | <1% | 2,266 | $65K | |
| 97116 | <1% | 6,381 | $65K | |
| 84439 | <1% | 29,423 | $65K | |
| 86480 | <1% | 5,052 | $64K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 12,395 | $64K |
| 90678 | <1% | 214 | $62K | |
| 83540 | <1% | 38,878 | $62K | |
| 87340 | <1% | 19,638 | $62K | |
| 82670 | <1% | 7,411 | $61K | |
| 93017 | <1% | 2,622 | $61K | |
| 86870 | <1% | 674 | $61K | |
| 73720 | <1% | 311 | $61K | |
| 93225 | <1% | 1,783 | $60K | |
| 86902 | <1% | 1,653 | $58K | |
| 64612 | <1% | 346 | $58K | |
| Q5102 | Injection, infliximab, biosimilar, 10 mg | <1% | 135 | $57K |
| 90746 | <1% | 1,043 | $57K | |
| 93798 | <1% | 1,089 | $57K | |
| 77290 | <1% | 381 | $57K | |
| 80074 | <1% | 6,807 | $57K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,373 | $56K |
| 31526 | <1% | 40 | $56K | |
| 82784 | <1% | 21,567 | $56K | |
| 72082 | <1% | 5,359 | $55K | |
| 84702 | <1% | 13,454 | $55K | |
| 72195 | <1% | 508 | $55K | |
| 47562 | <1% | 12 | $54K | |
| 97016 | <1% | 11,254 | $54K | |
| 92652 | <1% | 445 | $54K | |
| 47000 | <1% | 62 | $53K | |
| 72100 | <1% | 5,128 | $52K | |
| 88142 | <1% | 14,854 | $51K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 37 | $51K |
| 92585 | <1% | 465 | $51K | |
| 20552 | <1% | 473 | $51K | |
| 97763 | <1% | 967 | $51K | |
| 58300 | <1% | 3,146 | $50K | |
| 92083 | <1% | 9,763 | $50K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 4,352 | $50K |
| 77295 | <1% | 83 | $50K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 284 | $49K |
| 91122 | <1% | 402 | $48K | |
| 51705 | <1% | 513 | $47K | |
| 83735 | <1% | 67,814 | $46K | |
| 73523 | <1% | 881 | $46K | |
| 86850 | <1% | 39,532 | $46K | |
| 96402 | <1% | 2,980 | $46K | |
| 73700 | <1% | 840 | $46K | |
| 85610 | <1% | 68,068 | $46K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 4,161 | $46K |
| 92060 | <1% | 4,211 | $45K | |
| 83655 | <1% | 8,669 | $44K | |
| 97167 | <1% | 915 | $43K | |
| 99496 | <1% | 787 | $43K | |
| 84478 | <1% | 1,815 | $43K | |
| 74455 | <1% | 427 | $42K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 437 | $42K |
| 19318 | <1% | 12 | $42K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 3,761 | $42K |
| 96130 | <1% | 524 | $42K | |
| 73560 | <1% | 6,285 | $42K | |
| 87077 | <1% | 22,714 | $41K | |
| 86140 | <1% | 48,357 | $41K | |
| 91120 | <1% | 401 | $41K | |
| 90734 | <1% | 3,735 | $40K | |
| 74270 | <1% | 717 | $40K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,150 | $40K |
| 0002A | <1% | 1,035 | $38K | |
| 93351 | <1% | 173 | $38K | |
| 87536 | <1% | 2,952 | $38K | |
| 52310 | <1% | 52 | $38K | |
| 10022 | <1% | 152 | $37K | |
| 95115 | <1% | 2,071 | $37K | |
| 86762 | <1% | 7,994 | $37K | |
| 82746 | <1% | 9,338 | $37K | |
| 76870 | <1% | 2,145 | $37K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,082 | $36K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 16,217 | $36K |
| 90620 | <1% | 929 | $36K | |
| 87522 | Neg quan hep c or qual rna | <1% | 3,615 | $36K |
| 92522 | <1% | 685 | $35K | |
| 87497 | <1% | 6,203 | $35K | |
| J1611 | Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg | <1% | 593 | $35K |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 96 | $34K |
| 88185 | <1% | 2,359 | $34K | |
| 87631 | <1% | 7,318 | $34K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 3,430 | $34K |
| 73630 | <1% | 11,333 | $34K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,850 | $34K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 949 | $34K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,493 | $34K |
| 87799 | <1% | 6,625 | $33K | |
| 77072 | <1% | 2,760 | $33K | |
| 77373 | <1% | 33 | $33K | |
| 86360 | <1% | 4,398 | $33K | |
| 99406 | <1% | 2,333 | $32K | |
| 80069 | <1% | 16,389 | $32K | |
| 70544 | <1% | 569 | $32K | |
| 93750 | <1% | 670 | $31K | |
| 86003 | <1% | 4,019 | $31K | |
| 62270 | <1% | 133 | $31K | |
| 91200 | <1% | 810 | $30K | |
| 50200 | <1% | 38 | $30K | |
| 78492 | <1% | 71 | $30K | |
| 72146 | <1% | 552 | $30K | |
| 72050 | <1% | 2,195 | $30K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 33,612 | $30K |
| 81373 | <1% | 538 | $29K | |
| 73030 | <1% | 6,675 | $29K | |
| 92550 | <1% | 1,569 | $29K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,305 | $28K |
| 96118 | <1% | 490 | $28K | |
| 74220 | <1% | 493 | $28K | |
| 52356 | <1% | 16 | $28K | |
| 82533 | <1% | 5,940 | $28K | |
| 43760 | <1% | 259 | $28K | |
| 83001 | <1% | 5,804 | $28K | |
| 73564 | <1% | 6,064 | $28K | |
| 86160 | <1% | 8,549 | $27K | |
| 49452 | <1% | 69 | $27K | |
| 43248 | <1% | 132 | $27K | |
| 73130 | <1% | 7,043 | $27K | |
| 73610 | <1% | 6,665 | $27K | |
| 90716 | <1% | 9,915 | $27K | |
| 73521 | <1% | 3,029 | $27K | |
| 84481 | <1% | 5,642 | $26K | |
| 90662 | <1% | 1,556 | $26K | |
| 86359 | <1% | 4,352 | $26K | |
| 51726 | <1% | 169 | $26K | |
| 73502 | <1% | 4,712 | $25K | |
| 92511 | <1% | 294 | $25K | |
| 84146 | <1% | 4,571 | $24K | |
| 0001A | <1% | 658 | $24K | |
| 0004A | <1% | 753 | $24K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,310 | $23K |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion | <1% | 2,114 | $23K |
| 82024 | <1% | 2,220 | $23K | |
| 69210 | <1% | 2,817 | $23K | |
| 90656 | <1% | 2,754 | $22K | |
| 87186 | <1% | 15,386 | $22K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 6,746 | $22K |
| 84100 | <1% | 46,000 | $22K | |
| 31624 | <1% | 29 | $21K | |
| 0071A | <1% | 703 | $21K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 83 | $21K |
| 82105 | <1% | 8,205 | $21K | |
| 86769 | <1% | 849 | $21K | |
| 86038 | <1% | 10,679 | $21K | |
| 86146 | <1% | 2,160 | $21K | |
| 72083 | <1% | 413 | $21K | |
| 62252 | <1% | 143 | $21K | |
| 74019 | <1% | 3,216 | $20K | |
| 91010 | <1% | 96 | $20K | |
| 71271 | <1% | 400 | $20K | |
| 94003 | <1% | 151 | $20K | |
| 86706 | <1% | 8,669 | $20K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 289 | $20K |
| 73110 | <1% | 4,670 | $20K | |
| 74160 | <1% | 349 | $19K | |
| 92602 | <1% | 254 | $19K | |
| 87070 | <1% | 18,951 | $19K | |
| 94621 | <1% | 133 | $19K | |
| 0072A | <1% | 584 | $19K | |
| 82043 | <1% | 13,160 | $18K | |
| 83993 | <1% | 2,500 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,088 | $18K |
| 83002 | <1% | 4,063 | $18K | |
| 83615 | <1% | 26,029 | $18K | |
| 82950 | <1% | 6,025 | $17K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,468 | $17K |
| 87081 | <1% | 10,391 | $17K | |
| 81001 | <1% | 49,228 | $17K | |
| 85652 | <1% | 39,929 | $17K | |
| 87563 | <1% | 3,216 | $16K | |
| S9977 | Meals, per diem, not otherwise specified | <1% | 1,521 | $16K |
| 0124A | <1% | 548 | $16K | |
| 11982 | <1% | 148 | $16K | |
| 86665 | <1% | 2,678 | $15K | |
| 86225 | <1% | 7,280 | $15K | |
| 76813 | <1% | 322 | $15K | |
| 87517 | <1% | 1,414 | $15K | |
| 17250 | <1% | 771 | $15K | |
| 96523 | <1% | 1,214 | $15K | |
| 87529 | <1% | 1,675 | $15K | |
| 86147 | <1% | 2,278 | $15K | |
| 82088 | <1% | 1,473 | $15K | |
| 87338 | <1% | 2,006 | $15K | |
| 82565 | <1% | 10,124 | $15K | |
| 82378 | <1% | 5,672 | $14K | |
| 83021 | <1% | 4,459 | $14K | |
| 94799 | <1% | 7,592 | $14K | |
| 88307 | <1% | 4,261 | $14K | |
| 0054A | <1% | 412 | $14K | |
| G0010 | Administration of hepatitis b vaccine | <1% | 1,509 | $14K |
| 50435 | <1% | 14 | $14K | |
| 86704 | <1% | 5,780 | $14K | |
| 83516 | <1% | 6,323 | $13K | |
| 87205 | <1% | 22,559 | $13K | |
| 86355 | <1% | 2,917 | $13K | |
| 74240 | <1% | 207 | $13K | |
| 72131 | <1% | 387 | $13K | |
| 86901 | <1% | 39,921 | $13K | |
| 95812 | <1% | 93 | $13K | |
| 81025 | <1% | 32,092 | $13K | |
| 76885 | <1% | 575 | $13K | |
| 85730 | <1% | 33,090 | $13K | |
| 86357 | <1% | 2,245 | $13K | |
| 25605 | <1% | 20 | $12K | |
| 84156 | <1% | 20,688 | $12K | |
| 82550 | <1% | 13,272 | $12K | |
| 82785 | <1% | 5,038 | $12K | |
| 86923 | <1% | 4,418 | $12K | |
| 86334 | <1% | 3,531 | $12K | |
| 83690 | <1% | 30,839 | $12K | |
| 82627 | <1% | 1,964 | $12K | |
| 51784 | <1% | 292 | $12K | |
| 64635 | <1% | 12 | $12K | |
| 84445 | <1% | 957 | $11K | |
| 36593 | <1% | 73 | $11K | |
| 97035 | <1% | 2,109 | $11K | |
| 70498 | <1% | 1,189 | $11K | |
| 86787 | <1% | 3,216 | $11K | |
| 73590 | <1% | 3,839 | $11K | |
| 73140 | <1% | 2,490 | $11K | |
| 86364 | <1% | 4,390 | $11K | |
| 86922 | <1% | 1,000 | $11K | |
| 97803 | <1% | 2,549 | $11K | |
| 74221 | <1% | 141 | $11K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 58 | $11K |
| 81513 | <1% | 297 | $11K | |
| 11721 | <1% | 1,457 | $11K | |
| 64644 | <1% | 56 | $11K | |
| 62369 | <1% | 87 | $11K | |
| 29405 | <1% | 96 | $11K | |
| 54150 | <1% | 13 | $10K | |
| 72110 | <1% | 1,498 | $10K | |
| 73718 | <1% | 66 | $10K | |
| 84165 | <1% | 6,517 | $10K | |
| 86830 | <1% | 214 | $10K | |
| 76512 | <1% | 3,154 | $10K | |
| 84244 | <1% | 1,909 | $10K | |
| 86696 | <1% | 2,327 | $10K | |
| 76604 | <1% | 344 | $10K | |
| 84238 | <1% | 1,986 | $10K | |
| 87102 | <1% | 7,793 | $10K | |
| 88304 | <1% | 3,432 | $10K | |
| 92134 | <1% | 15,419 | $10K | |
| 73070 | <1% | 3,605 | $10K | |
| 83498 | <1% | 1,365 | $10K | |
| 84703 | <1% | 24,881 | $10K | |
| 93299 | <1% | 564 | $10K | |
| 92597 | <1% | 356 | $9K | |
| 83521 | <1% | 1,689 | $9K | |
| 95813 | <1% | 64 | $9K | |
| 92250 | <1% | 3,093 | $9K | |
| 86376 | <1% | 3,142 | $9K | |
| 86780 | <1% | 1,279 | $9K | |
| 72170 | <1% | 1,945 | $9K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 28 | $9K |
| 86580 | <1% | 1,655 | $9K | |
| 86800 | <1% | 2,597 | $9K | |
| 88313 | <1% | 1,747 | $9K | |
| 55250 | <1% | 13 | $9K | |
| 45331 | <1% | 27 | $9K | |
| 81003 | <1% | 34,755 | $9K | |
| 86831 | <1% | 214 | $9K | |
| 86200 | <1% | 4,573 | $9K | |
| 94618 | <1% | 1,707 | $8K | |
| 25600 | <1% | 83 | $8K | |
| 85246 | <1% | 1,548 | $8K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 103 | $8K |
| 84550 | <1% | 10,658 | $8K | |
| 84460 | <1% | 5,555 | $8K | |
| 81206 | <1% | 110 | $8K | |
| 90619 | <1% | 2,467 | $8K | |
| 85240 | <1% | 1,910 | $8K | |
| 77073 | <1% | 1,913 | $8K | |
| 17311 | <1% | 59 | $8K | |
| 78830 | <1% | 14 | $8K | |
| 43237 | <1% | 17 | $8K | |
| 84484 | <1% | 18,140 | $8K | |
| 72040 | <1% | 1,630 | $8K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 32 | $8K |
| 94664 | <1% | 2,421 | $8K | |
| 82977 | <1% | 5,258 | $8K | |
| 88112 | <1% | 2,860 | $8K | |
| 84153 | <1% | 2,125 | $7K | |
| 17999 | <1% | 108 | $7K | |
| 85045 | <1% | 11,040 | $7K | |
| 84450 | <1% | 5,014 | $7K | |
| 72072 | <1% | 757 | $7K | |
| 11055 | <1% | 169 | $7K | |
| 81207 | <1% | 110 | $7K | |
| 64721 | <1% | 13 | $7K | |
| 87902 | <1% | 247 | $7K | |
| 80164 | <1% | 2,200 | $7K | |
| 93246 | <1% | 827 | $7K | |
| 93325 | <1% | 10,364 | $7K | |
| 51798 | <1% | 9,000 | $7K | |
| 84305 | <1% | 1,794 | $7K | |
| 82803 | <1% | 30,606 | $7K | |
| 86695 | <1% | 2,317 | $7K | |
| 97802 | <1% | 1,555 | $7K | |
| 84480 | <1% | 1,811 | $7K | |
| 95715 | <1% | 31 | $7K | |
| 84630 | <1% | 2,886 | $7K | |
| 84425 | <1% | 1,975 | $7K | |
| 86708 | <1% | 3,153 | $7K | |
| 93242 | <1% | 522 | $7K | |
| 86664 | <1% | 2,391 | $7K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | <1% | 773 | $6K |
| 80158 | <1% | 953 | $6K | |
| 73552 | <1% | 2,235 | $6K | |
| 75635 | <1% | 66 | $6K | |
| 82330 | <1% | 27,112 | $6K | |
| 72084 | <1% | 118 | $6K | |
| 70355 | <1% | 1,424 | $6K | |
| 82525 | <1% | 2,329 | $6K | |
| 82652 | <1% | 779 | $6K | |
| 96401 | <1% | 381 | $6K | |
| 11981 | <1% | 204 | $6K | |
| 73562 | <1% | 898 | $6K | |
| 76818 | <1% | 105 | $6K | |
| 92553 | <1% | 312 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,583 | $6K |
| 0134A | <1% | 161 | $6K | |
| 81002 | <1% | 44,789 | $6K | |
| 84144 | <1% | 729 | $6K | |
| 84166 | <1% | 2,242 | $6K | |
| 11056 | <1% | 149 | $6K | |
| 93298 | <1% | 370 | $6K | |
| 86431 | <1% | 5,767 | $6K | |
| 86301 | <1% | 1,913 | $6K | |
| 82248 | <1% | 6,056 | $6K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 465 | $6K |
| 0081A | <1% | 167 | $6K | |
| 64505 | <1% | 38 | $6K | |
| 76506 | <1% | 232 | $6K | |
| 84432 | <1% | 1,525 | $6K | |
| 88365 | <1% | 299 | $6K | |
| 86255 | <1% | 2,756 | $5K | |
| 92133 | <1% | 7,341 | $5K | |
| 86765 | <1% | 1,136 | $5K | |
| 93925 | <1% | 55 | $5K | |
| 73100 | <1% | 2,209 | $5K | |
| 86644 | <1% | 2,328 | $5K | |
| 82962 | <1% | 43,119 | $5K | |
| 51701 | <1% | 3,155 | $5K | |
| 88312 | <1% | 900 | $5K | |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring | <1% | 66 | $5K |
| 94761 | <1% | 38,540 | $5K | |
| 0111A | <1% | 149 | $5K | |
| 73090 | <1% | 3,357 | $5K | |
| 72202 | <1% | 1,016 | $5K | |
| 83721 | <1% | 2,628 | $5K | |
| 72081 | <1% | 1,265 | $5K | |
| 82274 | <1% | 640 | $5K | |
| 87184 | <1% | 2,620 | $5K | |
| 82150 | <1% | 5,170 | $5K | |
| 92567 | <1% | 20,350 | $5K | |
| 82570 | <1% | 4,179 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,312 | $5K |
| 0012A | <1% | 133 | $5K | |
| 86304 | <1% | 1,661 | $5K | |
| 86735 | <1% | 955 | $5K | |
| 85245 | <1% | 894 | $5K | |
| 85598 | <1% | 1,761 | $5K | |
| 12032 | <1% | 65 | $5K | |
| 82951 | <1% | 621 | $5K | |
| 77332 | <1% | 72 | $5K | |
| 82247 | <1% | 3,181 | $5K | |
| 84134 | <1% | 2,580 | $5K | |
| 86663 | <1% | 1,915 | $5K | |
| 83520 | <1% | 3,651 | $5K | |
| 96380 | <1% | 438 | $5K | |
| 85397 | <1% | 558 | $5K | |
| 42975 | <1% | 78 | $4K | |
| 95806 | <1% | 59 | $4K | |
| 83525 | <1% | 1,019 | $4K | |
| 73600 | <1% | 1,972 | $4K | |
| 70546 | <1% | 68 | $4K | |
| 92591 | <1% | 101 | $4K | |
| 73060 | <1% | 1,340 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 40,188 | $4K |
| 84446 | <1% | 2,858 | $4K | |
| 84590 | <1% | 3,096 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,137 | $4K |
| 83921 | <1% | 1,375 | $4K | |
| 83605 | <1% | 26,305 | $4K | |
| 85379 | <1% | 5,844 | $4K | |
| 88344 | <1% | 114 | $4K | |
| 20605 | <1% | 29 | $4K | |
| 96111 | <1% | 63 | $4K | |
| 93312 | <1% | 24 | $4K | |
| 86341 | <1% | 1,259 | $4K | |
| 73000 | <1% | 683 | $4K | |
| 80162 | <1% | 1,577 | $4K | |
| 0003A | <1% | 124 | $4K | |
| 11200 | <1% | 289 | $4K | |
| 86300 | <1% | 1,540 | $4K | |
| 83010 | <1% | 2,165 | $4K | |
| 66821 | <1% | 14 | $4K | |
| 83835 | <1% | 804 | $4K | |
| Q0114 | Fern test | <1% | 752 | $4K |
| 84255 | <1% | 1,146 | $4K | |
| 94760 | <1% | 54,338 | $4K | |
| 92025 | <1% | 1,660 | $4K | |
| 80195 | <1% | 807 | $4K | |
| 57456 | <1% | 26 | $3K | |
| 45381 | <1% | 12 | $3K | |
| 0100U | <1% | 1,237 | $3K | |
| 93356 | <1% | 3,694 | $3K | |
| 17000 | <1% | 567 | $3K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 714 | $3K |
| 0011A | <1% | 90 | $3K | |
| 82390 | <1% | 2,317 | $3K | |
| 87040 | <1% | 6,968 | $3K | |
| 29085 | <1% | 46 | $3K | |
| 86317 | <1% | 233 | $3K | |
| 86677 | <1% | 843 | $3K | |
| 86039 | <1% | 2,329 | $3K | |
| 82310 | <1% | 2,882 | $3K | |
| 86777 | <1% | 1,468 | $3K | |
| 85384 | <1% | 2,122 | $3K | |
| 96376 | <1% | 21,872 | $3K | |
| 45330 | <1% | 13 | $3K | |
| 86256 | <1% | 1,409 | $3K | |
| 80178 | <1% | 1,343 | $3K | |
| 85014 | <1% | 4,520 | $3K | |
| 86352 | <1% | 117 | $3K | |
| 92285 | <1% | 2,864 | $3K | |
| 81370 | <1% | 14 | $3K | |
| 84681 | <1% | 859 | $3K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 15 | $3K |
| 0082A | <1% | 80 | $3K | |
| J3490 | Unclassified drugs | <1% | 9,415 | $3K |
| 93320 | <1% | 7,549 | $3K | |
| 85613 | <1% | 1,891 | $3K | |
| 92551 | <1% | 438 | $3K | |
| 69209 | <1% | 267 | $3K | |
| 73200 | <1% | 57 | $3K | |
| 87449 | <1% | 1,369 | $3K | |
| 75557 | <1% | 17 | $3K | |
| 87481 | <1% | 298 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 33 | $3K |
| 0121A | <1% | 89 | $3K | |
| 86141 | <1% | 924 | $3K | |
| 82085 | <1% | 2,000 | $3K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 2,531 | $3K |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | <1% | 77 | $3K |
| 64643 | <1% | 1,153 | $3K | |
| 82787 | <1% | 708 | $2K | |
| 86618 | <1% | 710 | $2K | |
| 82139 | <1% | 765 | $2K | |
| 92136 | <1% | 896 | $2K | |
| 0097U | <1% | 763 | $2K | |
| 96138 | <1% | 498 | $2K | |
| C8911 | Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium) | <1% | 77 | $2K |
| 0112A | <1% | 60 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 37 | $2K |
| 82379 | <1% | 908 | $2K | |
| 82166 | <1% | 182 | $2K | |
| 81244 | <1% | 37 | $2K | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 3,161 | $2K |
| 0064A | <1% | 59 | $2K | |
| 84410 | <1% | 429 | $2K | |
| 96136 | <1% | 1,125 | $2K | |
| 51702 | <1% | 144 | $2K | |
| 86880 | <1% | 1,137 | $2K | |
| 80175 | <1% | 706 | $2K | |
| 80169 | <1% | 338 | $2K | |
| 0154A | <1% | 50 | $2K | |
| 51600 | <1% | 678 | $2K | |
| 92020 | <1% | 935 | $2K | |
| 86645 | <1% | 408 | $2K | |
| 88262 | <1% | 300 | $2K | |
| 84132 | <1% | 9,705 | $2K | |
| 0074A | <1% | 75 | $2K | |
| 70460 | <1% | 14 | $2K | |
| 0051A | <1% | 50 | $2K | |
| 83090 | <1% | 349 | $2K | |
| 87797 | <1% | 478 | $2K | |
| 85018 | <1% | 22,244 | $2K | |
| 81243 | <1% | 38 | $2K | |
| 84436 | <1% | 948 | $2K | |
| 93041 | <1% | 8,607 | $2K | |
| 86008 | <1% | 185 | $2K | |
| 86015 | <1% | 722 | $1K | |
| 82140 | <1% | 924 | $1K | |
| 86036 | <1% | 946 | $1K | |
| 84145 | <1% | 3,147 | $1K | |
| 81376 | <1% | 14 | $1K | |
| C9145 | Injection, aprepitant, (aponvie), 1 mg | <1% | 123 | $1K |
| 95970 | <1% | 217 | $1K | |
| 88350 | <1% | 59 | $1K | |
| 91319 | <1% | 446 | $1K | |
| 64566 | <1% | 18 | $1K | |
| 76820 | <1% | 2,670 | $1K | |
| 80305 | <1% | 1,692 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,940 | $1K |
| 86381 | <1% | 343 | $1K | |
| 81406 | <1% | 13 | $1K | |
| 83051 | <1% | 1,146 | $1K | |
| 76776 | <1% | 31 | $1K | |
| 87209 | <1% | 147 | $1K | |
| 73522 | <1% | 189 | $1K | |
| 88346 | <1% | 58 | $1K | |
| 70250 | <1% | 653 | $1K | |
| 84155 | <1% | 2,047 | $1K | |
| 88237 | <1% | 300 | $1K | |
| 73120 | <1% | 396 | $1K | |
| 87486 | <1% | 1,314 | $1K | |
| 0013A | <1% | 36 | $1K | |
| 92555 | <1% | 1,777 | $1K | |
| 82010 | <1% | 1,333 | $1K | |
| 84295 | <1% | 9,454 | $1K | |
| 94642 | <1% | 846 | $1K | |
| 87581 | <1% | 1,314 | $1K | |
| 64447 | <1% | 32 | $1K | |
| 90381 | <1% | 292 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $1K |
| 87210 | <1% | 2,662 | $1K | |
| 88720 | <1% | 540 | $1K | |
| 00140 | <1% | 88 | $1K | |
| 92537 | <1% | 12 | $999.08 | |
| 82340 | <1% | 810 | $997.99 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 40 | $986.28 |
| 82542 | <1% | 768 | $932.83 | |
| 82164 | <1% | 504 | $903.70 | |
| 84300 | <1% | 1,283 | $881.17 | |
| 91318 | <1% | 499 | $864.03 | |
| 80299 | <1% | 527 | $862.58 | |
| 82157 | <1% | 128 | $850.43 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 27 | $843.66 |
| 93922 | <1% | 91 | $842.68 | |
| 92546 | <1% | 12 | $827.16 | |
| 82103 | <1% | 243 | $808.74 | |
| 74022 | <1% | 414 | $806.05 | |
| 99195 | <1% | 16 | $798.96 | |
| 82077 | <1% | 5,143 | $795.75 | |
| 76981 | <1% | 13 | $788.54 | |
| 94660 | <1% | 303 | $787.40 | |
| 88173 | <1% | 1,346 | $784.92 | |
| 86335 | <1% | 145 | $782.55 | |
| 74241 | <1% | 13 | $771.84 | |
| 82465 | <1% | 332 | $771.70 | |
| 96377 | <1% | 413 | $770.26 | |
| 94770 | <1% | 15 | $759.86 | |
| 87177 | <1% | 172 | $739.19 | |
| P9011 | Blood, split unit | <1% | 16 | $733.86 |
| 0052A | <1% | 19 | $713.07 | |
| 80165 | <1% | 374 | $709.80 | |
| 70481 | <1% | 12 | $704.41 | |
| 46600 | <1% | 266 | $685.40 | |
| 72052 | <1% | 42 | $684.34 | |
| 86231 | <1% | 430 | $672.62 | |
| 82239 | <1% | 113 | $668.54 | |
| 11720 | <1% | 66 | $654.92 | |
| 96101 | <1% | 34 | $635.94 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,146 | $615.68 |
| 72070 | <1% | 74 | $607.90 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 7,401 | $607.79 |
| 0031A | <1% | 19 | $605.60 | |
| 92201 | <1% | 983 | $603.27 | |
| 87116 | <1% | 2,040 | $589.20 | |
| 82365 | <1% | 446 | $583.42 | |
| 72128 | <1% | 15 | $567.80 | |
| 88264 | <1% | 105 | $558.47 | |
| 87385 | <1% | 282 | $557.10 | |
| 86829 | <1% | 13 | $547.90 | |
| 92226 | <1% | 340 | $540.19 | |
| 95974 | <1% | 14 | $525.51 | |
| 82172 | <1% | 50 | $523.45 | |
| 0141A | <1% | 13 | $521.07 | |
| 93280 | <1% | 96 | $509.67 | |
| 80230 | <1% | 426 | $506.06 | |
| 82610 | <1% | 3,571 | $493.98 | |
| 87501 | <1% | 173 | $474.36 | |
| 76821 | <1% | 163 | $463.42 | |
| 30901 | <1% | 54 | $458.99 | |
| 76516 | <1% | 50 | $458.50 | |
| 84207 | <1% | 63 | $444.59 | |
| 87206 | <1% | 2,601 | $443.53 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 92,407 | $441.03 |
| 90474 | <1% | 110 | $435.00 | |
| 83718 | <1% | 181 | $428.14 | |
| 83013 | <1% | 13 | $425.83 | |
| 86705 | <1% | 280 | $424.57 | |
| 73080 | <1% | 145 | $422.32 | |
| 80177 | <1% | 186 | $409.28 | |
| 0151A | <1% | 13 | $399.80 | |
| 92202 | <1% | 1,571 | $397.67 | |
| 93283 | <1% | 94 | $393.96 | |
| 83695 | <1% | 58 | $373.36 | |
| 90380 | <1% | 157 | $353.20 | |
| 93284 | <1% | 39 | $342.12 | |
| 85670 | <1% | 752 | $339.71 | |
| C1769 | Guide wire | <1% | 10,135 | $339.32 |
| 86308 | <1% | 1,261 | $331.43 | |
| 76937 | <1% | 3,448 | $331.32 | |
| 85576 | <1% | 20 | $329.14 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 11,608 | $324.03 |
| 82435 | <1% | 8,636 | $322.73 | |
| 11301 | <1% | 27 | $321.87 | |
| 87075 | <1% | 2,184 | $312.55 | |
| 94729 | <1% | 7,040 | $307.86 | |
| 90715 | <1% | 14,665 | $297.89 | |
| 95867 | <1% | 25 | $295.98 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 6,421 | $294.00 |
| 86593 | <1% | 111 | $291.68 | |
| 76377 | <1% | 11,952 | $290.55 | |
| 76513 | <1% | 42 | $286.22 | |
| 82017 | <1% | 148 | $285.61 | |
| 84520 | <1% | 441 | $282.41 | |
| G0288 | Reconstruction, computed tomographic angiography of aorta for surgical planning for vascular surgery | <1% | 1,277 | $271.42 |
| 87427 | <1% | 40 | $263.44 | |
| 86774 | <1% | 121 | $258.43 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 36,618 | $251.51 |
| 93321 | <1% | 902 | $249.90 | |
| 76514 | <1% | 1,174 | $249.20 | |
| 86162 | <1% | 49 | $243.78 | |
| 36592 | <1% | 58 | $241.14 | |
| 93282 | <1% | 38 | $240.49 | |
| 88172 | <1% | 791 | $240.23 | |
| 83935 | <1% | 128 | $236.00 | |
| 99407 | <1% | 19 | $233.58 | |
| 88300 | <1% | 2,710 | $231.37 | |
| J1815 | Injection, insulin, per 5 units | <1% | 9,732 | $227.58 |
| 29125 | <1% | 120 | $227.02 | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 325 | $224.69 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 6,215 | $222.45 |
| 80202 | <1% | 76 | $222.10 | |
| 87899 | <1% | 34 | $221.92 | |
| 0296T | <1% | 382 | $219.50 | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 4,087 | $214.97 |
| 89051 | <1% | 4,202 | $213.30 | |
| 96119 | <1% | 356 | $211.98 | |
| 86682 | <1% | 14 | $211.72 | |
| 87045 | <1% | 40 | $207.70 | |
| 88331 | <1% | 541 | $200.57 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 61,218 | $191.90 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 4,495 | $190.07 |
| 90723 | <1% | 15,650 | $181.20 | |
| 85250 | <1% | 36 | $179.93 | |
| 95976 | <1% | 12 | $178.00 | |
| 95885 | <1% | 1,759 | $173.72 | |
| 80143 | <1% | 3,110 | $164.89 | |
| 86648 | <1% | 84 | $163.33 | |
| 97032 | <1% | 21 | $162.05 | |
| 97018 | <1% | 89 | $161.64 | |
| 83930 | <1% | 134 | $158.81 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 5,176 | $151.16 |
| 90744 | <1% | 134 | $151.10 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 3,113 | $143.69 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 837 | $136.36 |
| 73503 | <1% | 27 | $135.20 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 6,371 | $133.64 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 126 | $127.76 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,618 | $123.92 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 578 | $118.43 |
| 87220 | <1% | 414 | $118.13 | |
| 99292 | <1% | 384 | $117.15 | |
| 76827 | <1% | 1,517 | $116.66 | |
| 76942 | <1% | 3,199 | $113.50 | |
| 83519 | <1% | 125 | $112.50 | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 21 | $108.51 |
| 82945 | <1% | 1,847 | $107.34 | |
| 12001 | <1% | 127 | $106.83 | |
| 88311 | <1% | 2,009 | $106.07 | |
| 82397 | <1% | 694 | $105.50 | |
| 80179 | <1% | 2,937 | $105.49 | |
| 84466 | <1% | 81 | $104.26 | |
| 86258 | <1% | 29 | $101.28 | |
| 92556 | <1% | 725 | $98.45 | |
| 89230 | <1% | 25 | $95.79 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 16,193 | $90.29 |
| 82656 | <1% | 25 | $85.86 | |
| 84080 | <1% | 24 | $83.65 | |
| 92570 | <1% | 360 | $83.03 | |
| 84157 | <1% | 2,065 | $80.90 | |
| 87207 | <1% | 26 | $79.14 | |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 413 | $77.95 |
| 83986 | <1% | 475 | $75.37 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 46,427 | $72.37 |
| 96120 | <1% | 209 | $69.39 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 38,357 | $65.20 |
| 87350 | <1% | 14 | $64.86 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,204 | $62.37 |
| 82985 | <1% | 13 | $60.53 | |
| 80156 | <1% | 25 | $59.86 | |
| 82668 | <1% | 14 | $57.47 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 57,914 | $55.91 |
| 86363 | <1% | 12 | $53.64 | |
| 86790 | <1% | 28 | $52.46 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 7,434 | $50.55 |
| Q9954 | Oral magnetic resonance contrast agent, per 100 ml | <1% | 1,130 | $50.40 |
| J2704 | Injection, propofol, 10 mg | <1% | 53,243 | $50.11 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 14,536 | $49.67 |
| 73660 | <1% | 12 | $48.48 | |
| 72220 | <1% | 12 | $48.48 | |
| 82040 | <1% | 54 | $45.58 | |
| 90707 | <1% | 10,050 | $43.05 | |
| 86828 | <1% | 13 | $42.28 | |
| 82725 | <1% | 25 | $41.00 | |
| 82731 | <1% | 26 | $40.48 | |
| 86337 | <1% | 12 | $38.69 | |
| 84270 | <1% | 1,067 | $38.50 | |
| 86316 | <1% | 13 | $38.34 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 7,417 | $38.01 |
| 85270 | <1% | 13 | $37.79 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,544 | $35.26 |
| C1729 | Catheter, drainage | <1% | 1,779 | $32.73 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 1,452 | $32.73 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,857 | $32.16 |
| 95024 | <1% | 392 | $31.95 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 25,831 | $31.21 |
| 90461 | <1% | 152 | $31.19 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 3,141 | $31.04 |
| 88302 | <1% | 67 | $31.04 | |
| 84704 | <1% | 12 | $28.38 | |
| 84163 | <1% | 12 | $28.38 | |
| 92225 | <1% | 343 | $28.34 | |
| 86701 | <1% | 120 | $27.90 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 65,743 | $27.38 |
| 90672 | <1% | 28 | $26.88 | |
| J1240 | Injection, dimenhydrinate, up to 50 mg | <1% | 638 | $25.09 |
| 94150 | <1% | 49 | $24.96 | |
| A9284 | Spirometer, non-electronic, includes all accessories | <1% | 3,539 | $24.77 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 19,792 | $23.47 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 6,219 | $22.87 |
| 95886 | <1% | 1,975 | $22.16 | |
| 85347 | <1% | 134 | $21.98 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 537 | $20.22 |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 963 | $20.18 |
| 86778 | <1% | 14 | $19.98 | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 25 | $17.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,177 | $16.09 |
| 85130 | <1% | 763 | $15.95 | |
| 96368 | <1% | 2,637 | $15.30 | |
| 82960 | <1% | 12 | $13.86 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 17,352 | $13.85 |
| 86709 | <1% | 28 | $13.30 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 9,544 | $13.20 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 117 | $12.46 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 131 | $12.46 |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 74 | $11.52 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 2,625 | $11.26 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 12,039 | $10.03 |
| 90700 | <1% | 5,174 | $10.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 19,193 | $9.16 |
| 86611 | <1% | 13 | $7.77 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 12 | $7.24 |
| 81000 | <1% | 114 | $7.05 | |
| 90680 | <1% | 13,082 | $7.00 | |
| 90633 | <1% | 10,475 | $7.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 13,340 | $6.92 |
| 87324 | <1% | 12 | $6.55 | |
| 80051 | <1% | 13 | $6.50 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,493 | $6.16 |
| 85291 | <1% | 12 | $6.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 45,168 | $5.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 16,979 | $5.10 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 8,999 | $4.06 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 4,086 | $3.96 |
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg | <1% | 89 | $3.61 |
| 82438 | <1% | 13 | $3.29 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 295 | $3.19 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,927 | $2.99 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 13,172 | $2.85 |
| 99177 | <1% | 41 | $2.46 | |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 37 | $2.42 |
| A4615 | Cannula, nasal | <1% | 538 | $2.29 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 5,761 | $2.10 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 5,241 | $1.83 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12,768 | $1.79 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 4,390 | $1.74 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,389 | $1.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,601 | $1.11 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 7,352 | $1.04 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,299 | $0.92 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,708 | $0.91 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,568 | $0.43 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,784 | $0.41 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 338 | $0.17 |
| J7517 | Mycophenolate mofetil, oral, 250 mg | <1% | 23 | $0.09 |
| 97139 | <1% | 331 | $0.05 | |
| 91307 | <1% | 1,206 | $0.02 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 275 | $0.01 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 3,299 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 804 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,883 | $0.00 |
| 90632 | 0% | 925 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 1,814 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 1,360 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 444 | $0.00 |
| 96131 | 0% | 357 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 1,839 | $0.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 684 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 1,304 | $0.00 |
| 0399T | 0% | 417 | $0.00 | |
| 90696 | 0% | 4,358 | $0.00 | |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 0% | 123 | $0.00 |
| J9250 | Methotrexate sodium, 5 mg | 0% | 328 | $0.00 |
| 83883 | 0% | 1,239 | $0.00 | |
| 77001 | 0% | 378 | $0.00 | |
| 97010 | 0% | 5,784 | $0.00 | |
| 82104 | 0% | 856 | $0.00 | |
| C2627 | Catheter, suprapubic/cystoscopic | 0% | 458 | $0.00 |
| 90636 | 0% | 698 | $0.00 | |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 1,011 | $0.00 |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 3,921 | $0.00 |
| 91315 | 0% | 90 | $0.00 | |
| 87176 | 0% | 384 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 49 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 1,060 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 760 | $0.00 |
| G0268 | Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing | 0% | 122 | $0.00 |
| 91317 | 0% | 57 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 811 | $0.00 |
| 95012 | 0% | 233 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 225 | $0.00 |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | 0% | 12 | $0.00 |
| 90647 | 0% | 15,387 | $0.00 | |
| 51797 | 0% | 174 | $0.00 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 0% | 409 | $0.00 |
| 99459 | 0% | 461 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 651 | $0.00 |
| 95940 | 0% | 269 | $0.00 | |
| 82657 | 0% | 305 | $0.00 | |
| 36000 | 0% | 2,655 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 226 | $0.00 |
| 96121 | 0% | 293 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 320 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 20 | $0.00 |
| 96139 | 0% | 397 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 52 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 108 | $0.00 |
| 92542 | 0% | 24 | $0.00 | |
| 64494 | 0% | 53 | $0.00 | |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 0% | 164 | $0.00 |
| 91305 | 0% | 634 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 305 | $0.00 |
| 87154 | 0% | 13 | $0.00 | |
| 92541 | 0% | 25 | $0.00 | |
| J9209 | Injection, mesna, 200 mg | 0% | 133 | $0.00 |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 2,023 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 140 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 45 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 75 | $0.00 |
| 74330 | 0% | 14 | $0.00 | |
| 76998 | 0% | 12 | $0.00 | |
| C1755 | Catheter, intraspinal | 0% | 71 | $0.00 |
| Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg | 0% | 19 | $0.00 |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 71 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 41 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 31 | $0.00 |
| 91314 | 0% | 33 | $0.00 | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 24 | $0.00 |
| 87071 | 0% | 29 | $0.00 | |
| 83919 | 0% | 12 | $0.00 | |
| C2629 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, laser | 0% | 39 | $0.00 |
| 91306 | 0% | 44 | $0.00 | |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | 0% | 27 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 652 | $0.00 |
| A6214 | Foam dressing, wound cover, sterile, pad size more than 48 sq. in., with any size adhesive border, each dressing | 0% | 12 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 648 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 637 | $0.00 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 4,393 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 2,579 | $0.00 |
| 91311 | 0% | 242 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 1,280 | $0.00 |
| J9171 | Injection, docetaxel, 1 mg | 0% | 56 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 1,009 | $0.00 |
| 82075 | 0% | 109 | $0.00 | |
| A9548 | Indium in-111 pentetate, diagnostic, per 0.5 millicurie | 0% | 638 | $0.00 |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 1,812 | $0.00 |
| J9370 | Vincristine sulfate, 1 mg | 0% | 2,551 | $0.00 |
| 95873 | 0% | 491 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 1,949 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 2,831 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 800 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 219 | $0.00 |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 0% | 583 | $0.00 |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | 0% | 636 | $0.00 |
| 96133 | 0% | 1,666 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 527 | $0.00 |
| 90785 | 0% | 4,558 | $0.00 | |
| 92504 | 0% | 834 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 2,519 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 145 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 156 | $0.00 |
| 96137 | 0% | 987 | $0.00 | |
| 97602 | 0% | 13 | $0.00 | |
| 90836 | 0% | 455 | $0.00 | |
| C2625 | Stent, non-coronary, temporary, with delivery system | 0% | 46 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 140 | $0.00 |
| 90714 | 0% | 506 | $0.00 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 848 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 29 | $0.00 |
| 76376 | 0% | 897 | $0.00 | |
| 90713 | 0% | 392 | $0.00 | |
| 77002 | 0% | 137 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 488 | $0.00 |
| J9260 | Injection, methotrexate sodium, 50 mg | 0% | 431 | $0.00 |
| 91312 | 0% | 640 | $0.00 | |
| 95874 | 0% | 103 | $0.00 | |
| 96113 | 0% | 26 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 301 | $0.00 |
| 17003 | 0% | 126 | $0.00 | |
| 91308 | 0% | 293 | $0.00 | |
| J7070 | Infusion, d5w, 1000 cc | 0% | 81 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 246 | $0.00 |
| 91300 | 0% | 699 | $0.00 | |
| 91313 | 0% | 147 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 156 | $0.00 |
| 11101 | 0% | 93 | $0.00 | |
| 75565 | 0% | 64 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 219 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 118 | $0.00 |
| A6446 | Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard | 0% | 60 | $0.00 |
| A6253 | Specialty absorptive dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing | 0% | 175 | $0.00 |
| 64636 | 0% | 12 | $0.00 | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 50 | $0.00 |
| 11105 | 0% | 12 | $0.00 | |
| 82805 | 0% | 144 | $0.00 | |
| J9206 | Injection, irinotecan, 20 mg | 0% | 435 | $0.00 |
| 12011 | 0% | 156 | $0.00 | |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 0% | 40 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 12 | $0.00 |
| 96152 | 0% | 18 | $0.00 | |
| P9073 | Platelets, pheresis, pathogen-reduced, each unit | 0% | 124 | $0.00 |
| 11103 | 0% | 38 | $0.00 | |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 67 | $0.00 |
| J9255 | Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg | 0% | 14 | $0.00 |
| 77387 | 0% | 50 | $0.00 | |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, DAVID (PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.